Abstract
Cardiac troponin (cTn) is one of the most widely used biomarkers in clinical care and biomedical research. Compared to the MB fraction of creatine kinase (CK-MB), cTn is the preferred biomarker for detecting myocardial necrosis because of its high myocardial tissue specificity and high clinical sensitivity. Although an elevated cTn value reflects injury leading to myocardial necrosis, the underlying mechanism may be difficult to ascertain. Such mechanisms may be ischemic, nonischemic, or analytical in origin and can only be determined by considering the clinical context in which the measurement is made.
The chapter discusses a general approach to the clinical interpretation of cTn elevation and how an acute myocardial infarction may be differentiated from other etiologies.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Alpert JS, Thygesen K, Antman E, et al. Myocardial infarction redefined: a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol. 2000;36(3):959–69.
Thygesen K, Alpert JS, White HD, on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. J Am Coll Cardiol. 2007;50(22):2173–95.
Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction. Third universal definition of myocardial infarction. J Am Coll Cardiol. 2012;60(16):1581–98.
Newby LK, Jesse RL, Babbb JD, Christenson RH, De Fer TM, Diamond GA, Fesmire FM, Geraci SA, Gersh BJ, Larsen GC, Kaul S, McKay CR, Philippides GJ, Weintraub WS, ACCF. Expert consensus document on practical clinical considerations in the interpretation of troponin elevations. J Am Coll Cardiol. 2012;60(23):2427–63.
Nomenclature and criteria for diagnosis of ischemic heart disease. Report of the Joint International Society and Federation of Cardiology/World Health Organization task force on standardization of clinical nomenclature. Circulation. 1979;59(3):607–9.
Moussa ID, Klein LW, Shah B, Mehran R, Mack MJ, Brilakis ES, Reilly JP, Zoghbi G, Holper E, Stone GW. Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization. An expert consensus document from the Society for Cardiovascular Angiography and Interventions (SCAI). J Am Coll Cardiol. 2013;62(17):1563–70.
White HD. Torrent of troponin. Circ Cardiovasc Interv. 2014;7:435–9.
Anderson JL, Adams CD, Antman EM, et al. 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction. J Am Coll Cardiol. 2013;61(23):e179–347.
Braunwald E, Morrow DA. Unstable angina: is it time for a requiem? Circulation. 2013;127:2452–7.
Kociol RD, Pang PS, Gheorghiade M, Fonarow GC, O’Connor CM, Felker GM. Troponin elevation in heart failure. J Am Coll Cardiol. 2010;56(14):1071–8.
Peacock WF, De Marco T, Fonarow GC, et al. Cardiac troponin and outcome in acute heart failure. N Eng J Med. 2008;358:2117–26.
Wilson Tang WH, Francis GS, Morrow DA, Newby LK, Cannon CP, Jesse RL, Storrow AB, Christenson RH. National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: clinical utilization of cardiac biomarker testing in heart failure. Circulation. 2007;116:e99–109.
Becattini C, Vedovatia MC, Agnelli G. Prognostic value of troponins in acute pulmonary embolism: focus on serum troponins. Expert Rev Mol Diagn. 2008;8(3):339–49.
Beccattini C, Vedovati MC, Agnelli G. Prognostic value of troponins in acute pulmonary embolism: a meta-analysis. Circulation. 2007;116:427–33.
Khan NA, Hemmelgarn BR, Tonelli M, et al. Prognostic value of troponin T and I among asymptomatic patients with end-stage renal disease: a meta-analysis. Circulation. 2005;112:3088–96.
Wu AH, Jaffe AS, Apple FS, et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines: use of cardiac troponin and B-type natriuretic peptide or N-terminal proB-type natriuretic peptide for etiologies other than acute coronary syndromes and heart failure. Clin Chem. 2007;53:2086–96.
Shapiro BP, Jaffe AS. Cardiac biomarkers. In: Murphy JG, Lloyd MA, editors. Mayo clinic cardiology: concise textbook. 3rd ed. Rochester: Mayo Clinic Scientific Press; 2007. p. 773–80. New York: Informa Healthcare USA.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Additional information
Disclaimer
This chapter reflects the views of the author and should not be construed to represent FDA’s views or policies.
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Hicks, K.A. (2015). Circulating Cardiac Troponins as Specific Biomarkers of Myocardial Damage: Clinical Considerations. In: Jagadeesh, G., Balakumar, P., Maung-U, K. (eds) Pathophysiology and Pharmacotherapy of Cardiovascular Disease. Adis, Cham. https://doi.org/10.1007/978-3-319-15961-4_11
Download citation
DOI: https://doi.org/10.1007/978-3-319-15961-4_11
Publisher Name: Adis, Cham
Print ISBN: 978-3-319-15960-7
Online ISBN: 978-3-319-15961-4
eBook Packages: MedicineMedicine (R0)